TG Therapeutics Earnings Call Highlights BRIUMVI Surge

TG Therapeutics ((TGTX)) has held its Q4 earnings call. Read on for the main highlights of the call.

TG Therapeutics’ latest earnings call struck an upbeat tone, underscoring powerful revenue momentum for BRIUMVI, a deepening data moat, and a pipeline stacked with near‑term catalysts. Management balanced this optimism with reminders about one‑off tax benefits, near‑term margin pressure, and elevated spending, but overall projected confidence in sustaining growth and cash generation.

Explosive Revenue Growth and Quarterly Acceleration

Full‑year 2025 global revenue reached roughly $616 million, powered mainly by about $594 million in U.S. BRIUMVI net sales that underscore rapid adoption in multiple sclerosis. In Q4 2025, U.S. net sales of $182.7 million drove total product revenue of $189.1 million, marking approximately 92% year‑over‑year growth and about 20% sequential growth versus Q3.

Adjusted Profitability Masks One‑Time Boost to Earnings

TG posted 2025 operating income of $123 million, signaling an underlying business that is already solidly profitable on an adjusted basis. However, reported net income jumped to $447.2 million, or $2.77 per diluted share, largely due to a roughly $340 million nonrecurring tax benefit that investors should strip out when gauging sustainable earnings power.

Long‑Term Clinical Data Strengthen BRIUMVI’s Competitive Position

Six‑year open‑label extension data from the ULTIMATE I and II trials showed nearly 90% of patients remained free from 24‑week confirmed disability progression, with relapse rates as low as one event per roughly 83 patient‑years. The absence of new safety signals is reinforcing neurologists’ confidence in BRIUMVI, helping drive strong patient persistence and supporting continued share gains in multiple sclerosis.

Pipeline Catalysts Build a Multi‑Year Growth Runway

Management highlighted a series of late‑stage and earlier‑stage programs that could materially expand the franchise beyond IV BRIUMVI. The ENHANCE Phase III trial of a single 600 mg infusion has completed enrollment with topline data expected in mid‑2026, while a subcutaneous BRIUMVI Phase III is about 75% enrolled with pivotal readout targeted for late 2026 or early 2027 and a potential 2028 launch.

2026 Guidance Signals Confidence in Sustained Growth

The company reaffirmed 2026 U.S. BRIUMVI net revenue guidance of $825 million to $850 million and total global revenue of $875 million to $900 million, indicating management sees growth continuing at a healthy clip. For Q1 2026, TG expects U.S. revenue of roughly $185 million to $190 million, which implies sequential growth over Q4 even after factoring in normal early‑year reimbursement headwinds.

Balance Sheet Strength and Shareholder Returns

TG closed 2025 with more than $600 million in current assets, including about $200 million in cash, cash equivalents, and investments, approximately $300 million in accounts receivable, and around $140 million of inventory. The company completed a $100 million share repurchase program at an average price of $28.55 and secured authorization for another $100 million, all while signaling expectations for ongoing positive cash flow from 2026.

Commercial Execution Drives Market Share Gains

Management pointed to broad‑based BRIUMVI growth across both academic and community practices, with a steadily expanding prescriber base and record levels of new patient enrollments. Strong persistence, coupled with operational advantages such as a one‑hour, twice‑yearly maintenance infusion schedule, is helping BRIUMVI win share within the IV anti‑CD20 segment despite entrenched competitors.

Headline Net Income Distorted by One‑Time Tax Release

While the sharp jump in 2025 net income may catch investors’ attention, TG emphasized that roughly $340 million of that figure reflects a one‑off tax benefit from releasing a deferred tax asset valuation allowance. As a result, the reported $447.2 million bottom line overstates recurring profitability, and the more modest operating income figure offers a clearer view of ongoing performance.

Margins Pinched by Inventory Reserve and Mix

Quarterly gross margins ran slightly below typical levels due to a combination of timing on sales to the company’s ex‑U.S. partner and a one‑time inventory reserve. These factors created short‑term margin pressure that management framed as transient rather than structural, with expectations that profitability metrics should normalize as these items roll off.

Rising Costs Reflect Subcutaneous Bet and Scale‑Up

Operating expenses for 2025, excluding noncash compensation, totaled about $328 million and landed slightly above the prior $300 million to $320 million guide thanks mainly to added manufacturing and development costs tied to subcutaneous BRIUMVI. For 2026, TG is planning around $350 million of operating expenses plus roughly $100 million of subcutaneous manufacturing and secondary‑manufacturer start‑up costs, underscoring the scale of its investment in future growth.

Seasonal Gross‑to‑Net Headwinds Cloud Early‑Year Revenue

Management cautioned that Q1 revenue will be affected by familiar industry dynamics such as benefit reverifications, deductible resets, and heavier reliance on co‑pay programs, which can elevate gross‑to‑net discounts. These seasonal effects may temporarily dampen reported net revenue even as underlying demand and new patient starts remain robust and are already factored into full‑year guidance.

Subcutaneous Market Offers Upside but Raises Execution Risk

TG sees subcutaneous BRIUMVI as a major TAM expansion opportunity that could nearly double the addressable market, but acknowledged intensifying competition from larger players like Roche and Novartis that are also pushing subcutaneous options. Success will depend on clean Phase III data and flawless execution in a crowded, fast‑evolving subcutaneous landscape where differentiation and launch timing will be critical.

Dependence on Upcoming Trial Readouts

Investors were reminded that much of TG’s mid‑to‑late decade growth narrative rests on pivotal trial milestones, including ENHANCE topline results in mid‑2026 and the subcutaneous Phase III readout expected late 2026 or early 2027. Any delays or disappointing outcomes could significantly disrupt the projected 2027 to 2028 commercialization timeline and temper expectations for step‑change revenue expansion.

Guidance and Outlook Emphasize Growth and Investment

On the call, management reiterated 2026 revenue targets and laid out an expense framework that balances growth with disciplined investment, including about $350 million of operating costs and roughly $100 million earmarked for subcutaneous manufacturing ramp‑up. They highlighted strong current‑asset levels, ongoing share repurchase capacity, and expectations for continuing positive cash flow as proof that TG can fund its ambitious pipeline while still rewarding shareholders.

TG Therapeutics’ earnings call painted the picture of a company with a fast‑growing core asset, increasingly persuasive long‑term data, and a loaded catalyst calendar, offset by understandable concerns around one‑time accounting boosts and rising spend. For investors comfortable with clinical and execution risk, management’s confident tone and reaffirmed guidance suggest the BRIUMVI story still has considerable room to run.